Introduction
Interleukin-2 (IL-2) has been shown to play a critical role in the regulation of proliferation and differentiation of hematopoietic cells. This IL-2-mediated regulation is dependent on expression of the IL-2 receptor (IL-2R) protein on the cell surface of target cells (Robb et al., 1981; Taniguchi et al., 1986) . At least three types of molecules (a, b and g) have been identi®ed as components of IL-2R (Siegel et al., 1987; Takeshita et al., 1992) and dierent combinations of these components are responsible for IL-2Rs with various anities for the ligand, IL-2 (Taniguchi and Minami, 1993; Waldmann, 1989) . The g chain of IL-2R is shared by several types of cytokine receptors (Kondo et al., 1993) . The b chain has been recently identi®ed as a component of receptor for IL-15 (Giri et al., 1994) . The b chain of IL-2R appears to be essential for signaltransduction and for association with p56 lck , a protein tyrosine kinase involved in IL-2-induced signaling (Hatakeyama et al., 1989a,b; Tsudo et al., 1989) . It has a cytoplasmic tail consisting of 286 amino acids and including three unique regions: acidic, serine-rich, and proline-rich (Hatakeyama et al., 1989a (Hatakeyama et al., ,b, 1991 . In contrast, the IL-2Ra chain is not involved in IL-2-mediated intracellular signal transduction (Hatakeyama et al., 1989a,b) .
In normal hematopoietic cells, IL-2 induces a positive signal leading to cytokine production and cellular proliferation (Waldmann, 1989) . In contrast, some human tumor cells respond to IL-2 by inhibition of cellular proliferation (Weidmann et al., 1992) . Our previous data have shown that exogenous IL-2 at micromolar concentrations induces growth inhibition in squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC) and gastric carcinoma cell (HR) lines in vitro (Yasumura et al., 1994) and of SCCHN tumors in vivo (Rabinowich et al., 1992) . Furthermore, this inhibition of growth was mediated via the IL-2Rb chain, because monoclonal antibodies speci®c for IL-2Rb chain were able to reverse it (Yasumura et al., 1994; Lin et al, 1995) . These observations indicated that in carcinomas, the IL-2Rb chain was involved in delivery of a negative signal to the nucleus. One possible explanation for the observed phenomenon was that IL-2Rb chain expressed on tumor cells was structurally dierent from that expressed in lymphoid cells. To investigate this possibility, we analyzed expression of IL-2Rb by reverse transcription-PCR (RT ± PCR) in the tumor cell lines which were inhibited in growth by exogenous IL-2. Several pairs of sense-antisense primers for dierent regions of the IL-2Rb chain message were used for cDNA ampli®cation. Furthermore, we analyzed the sequence of the IL-2R gene coding for the cytoplasmic region of the b chain, using DNA obtained from a SCCHN cell line, which was inhibited in growth by exogenous IL-2. The results of this molecular analysis are supported by immunoprecipitation studies and indicate that human carcinomas and lymphocytes express the same IL-2Rb chain. Another possibility we considered was that altered IL-2 signaling may be a result of changes in the g chain of IL-2R in tumor cells, including dierences in the pro®le of Janus kinases (JAK1 and JAK3) associated with the b and g chains of IL-2R, respectively. Our results suggest that tumor cells express transcripts for dierent splice variants of JAK3 than do normal lymphocytes.
Results

Negative growth signals delivered by exogenous IL-2
We have previously reported the presence of IL-2R b chain on various human carcinomas. (Weidmann et al., 1992; Yasamura et al., 1994; Lin et al., 1995) . By immunoperoxidase staining or¯ow cytometry, the receptor is detectable both on the surface of cultured tumor cells and in their cytoplasm ( Figure 1a ). It is also detectable by immunoperoxidase staining on cryostat sections of carcinoma tissues, as shown in Figure 1b . Messenger RNA for IL-2Rb chain is detectable in tumor cells by RT ± PCR, as reported previously (Lin et al., 1995) . The receptor is functional, since it binds exogenous 125 I-labeled IL-2, and one of the biologic consequences of IL-2 binding to the receptor expressed on carcinomas is inhibition of tumor growth (Lin et al., 1995) . As seen in Figure 2 , a squamous carcinoma cell line incubated in the presence of IL-2 was inhibited in growth, and the level of inhibition increased with increasing concentrations of exogenous IL-2. At the same time, IL-15, which is known to bind to the same b chain of IL-2R, did not induce growth inhibition. This result could be attributed to a requirement of IL-15 for a distinct receptor chain or to the presence in tumor cells of endogenus IL-15 capable of competing with the recombinant ligand for binding to the receptor.
RT ± PCR analysis of IL-2R gene expression in tumor cells
Because in lymphoid cells, binding of IL-2 to IL-2R induces growth, and the IL-2Rb chain is a critical signal-transducing component of the receptor, we wondered whether negative signaling seen in carcinoma cell lines incubated with exogenous IL-2 re¯ected the presence of a spliced or truncated version of the receptor in tumor cells. To test the hypothesis that carcinomas express IL-2Rb chain, which mediates negative growth signals and thus diers from the lymphoid IL-2RBb, mRNA was obtained from tumor and control lymphoid cells. Using a series of paired sense-antisense primers, spanning the length of the gene (exons 1 ± 10; 1.7 kb coding region for the IL-2Rb chain) RT ± PCR was performed to determine whether evidence for alternative splicing could be obtained (Figure 3 ). For every pair of primers used, we con®rmed the identity of the PCR-ampli®ed product by Southern analysis with 32 P-labeled cDNA probe coding for the entire span of the IL-2Rb chain.
First, with the primer pair (273232 ± 262797), which covers the extracellular region of the IL-2Rb molecule (Table 1) , the RT ± PCR products obtained from tumor cells and control cells were found to be identical in size. Their identity was con®rmed by Southern blotting, using 32 P-labeled IL-2Rb cDNA (Figure 4a) . Similarly, when we used the primer pairs, which covered the transmembrane region or the N-terminal end of the intracellular region (Table 1) , including the serine-rich and acidic sites, the respective PCR products were of the same size in tumor and control cells (Figure 4b ). However, when we used two sets of primer pairs which cover the C-terminal end of the intracellular region of the IL-2Rb chain (Table 1) , we were at ®rst unable to Figure 1 Immunostaining for IL-2Rb chain, using mAb TU27. In (a) a SCCHN cell line monolayer was dissociated, and cytospins of individual cells were ®xed and stained by immunoperoxidase. In (b) a cryostat tissue section of a carcinoma of the larynx stained by immunoperoxidase, using the same mAb. Note granular intracytoplasmic staining in carcinoma cells. The scale bar=25 m obtain an RT ± PCR product from tumor cells, although cDNA obtained from control lymphoid cells was ampli®ed normally (data not shown). This failure to amplify transcripts downstream from the nucleotide position 1292 in exon 10 tentatively suggested that the IL-2Rb transcript was truncated in tumor cells or that a cryptic splice site was present in exon 10.
On the other hand, it was possible that the primer pairs we used failed to hybridize with cDNA from tumor cells. In attempting to resolve this problem, various concentrations of MgCl 2 and dierent anneal- Shibuya et al., 1990) , indicating exons 1 ± 10, nucleotides, and regions coding for extracellular, transmembrane and cytoplasmic domains. Representative pairs of primers, which span the entire coding region were used for ampli®cation of cellular RNA and sequencing, are listed in the lower part of the diagram ing temperatures, as well as products known to reduce mishybridization, were used, but without a success. We then designed additional primer pairs spanning the intracytoplasmic domain of the gene (Table 1) and repeated PCR and Southern hybridization. These experiments showed no dierence in the size of expected PCR products between tumor and lymphoid cells. Southern hybridization to 32 P-labeled cDNA for IL-2Rb con®rmed the identity of the products ( Figure  5 ). From these results, obtained in at least three independent experiments, we concluded that human carcinomas and lymphocytes express the same IL-2Rb chain. Northern analyses, using total cellular mRNA or poly A + mRNA obtained from tumor and control cells con®rmed a lack of any dierence in the size of 4 kb message for IL-2Rb chain in these cells (data not shown).
Sequencing analysis of genomic DNA
To further con®rm that the IL-2Rb chain transcripts in the intracytoplasmic region between nt. 1240 and 1840 were identical in tumor and control lymphoid cells, genomic DNA was obtained from PCI-1 and control YT cells and ampli®ed by PCR, using the following primers: 1240S ± 1516A and 1403S ± 1840A (Table 1) . Direct sequencing of the ampli®ed cDNA showed no evidence of mutation or deletion. These results were further con®rmed by SSCP analysis (data not shown).
Immunoprecipitation and Western blot analysis
Monoclonal antibody (TU27) to the ligand-binding site on the IL-2Rb chain was used to immunoprecipitate the protein from lysates of tumor (HR) and control YT cells prior to Western blotting. As shown in Figure 6 , the band corresponding to IL-2Rb chain has the same electrophoretic mobility in lysates of tumor and control lymphoid cells.
Expression of IL2Rg chain in carcinomas
Because the g c chain is a functional component of IL-2R associated with the b chain, its expression in carcinoma cells was also investigated, using anti-human g chain antibodies. By¯ow cytometry and immunoperoxidase staining, the g chain protein was detectable in tumor cells (Table 2 and Figure 7) , and we have previously demonstrated the presence of g chain mRNA in these cells by RT ± PCR, RNase protection assays in situ hybridization (Yasamura et al., 1994; Lin et al., 1993) . As shown in Table 2 , intracytoplasmic expression of the g c chain was detectable in nearly all carcinoma cells. The antibody we used for these studies IB: Figure 6 Expression of IL-2Rb in HR cells. HR and YT cells (30610 6 cells/lane) were lysed, and immunoprecipitated by IL2Rb-speci®c TU27 mAb and protein A-Sepharose beads. The immunoprecipitates were resolved on reducing 10% SDS ± PAGE gels, and proteins transferred to a nitrocellulose membrane were blotted with anti-IL-2Rb mAb 341 (2 mg/ml). Protein bands were detected by enhanced chemiluminescence. IP=immunoprecipita-tion; IB=immunoblotting does not bind to the extracellular domain of the g chain and interacts only with its cytoplasmic portion (Noguchi et al., 1993) .
JAK1 and JAK3 expression in carcinomas
In lymphocytes, signaling via the bg chains of IL-2R involves activation of JAK1 and JAK3 (Johnston et al., 1966) . We performed RT ± PCR to compare expression of mRNAs for these kinases in our tumor cell lines (PCI-1 and HR) and in lymphocytes (Con Aactivated blasts and Jurkat cells). Figure 8 shows that JAK1 transcripts were expressed both in lymphocytes used as controls and in the tumor cells. Since it has been reported that various combinations of JA3 splice variants at the COOH terminals may be expressed in non-hematopoietic cells (Lai et al., 1995) , RT ± PCR analysis was employed to determine the expression pattern of the common JAK3 and its splice variants (S, B and M) in the carcinoma cells. RT ± PCR results shown in Figure 8 indicate that while 233 bp PCR fragment of the S form of JAK3 was detected at approximately equal levels in all the cells examined, the common JAK3 transcript was not expressed in HR cells, the B form transcript of JAK3 was absent in all the tumor cell lines, and the M form was present in Jurkat and PCI-1 cells at low levels and was not detected in HR. These results suggest that dierences in expressions of JAK3 splice variants exist in tumor cells vs. normal lymphocytes, which could account for dierences in the downstream signaling of JAK3.
Discussion
Our previous data have shown that exogenous IL-2 inhibited growth of human tumor cell lines (Weidmann et al., 1992; Yasumura et al., 1994) , which expressed abundant IL-2Rb chains and a very low number of IL2Ra chains (Yasumura et al., 1994) . We hypothesized that the IL-2Rb molecule expressed on tumor cells might be dierent from that expressed on hematopoietic cells, because it was responsible for delivery of a negative growth signal to tumor cells. IL-2Rb is a membrane protein, which is comprised of the extracellular, transmembrane and cytoplasmic regions (Hatakeyama et al., 1989a,b) . The extracellular regions contains the WS motifs (Trp-Ser-X-Trp-Ser), which have been shown to be essential for receptor folding to generate the IL-2 binding site (Miyazaki et al., 1991) . In the intracytoplasmic region, three unique sites (serine-rich, acidic and proline-rich) exist. The serinerich site is commonly found in the cytoplasmic region of other cytokine receptors and is considered to be essential for mediating the ligand-induced cellular proliferation signal . The acidic site is responsible for the interaction with p56 lck . The proline-rich site has a tyrosine residue required for interaction with STAT5, which is activated by IL-2 (Taniguchi, 1995) . The possibility existed that a structural alteration of one of these sites, for example, a mutation, present in tumor cells but not normal hematopoietic cells, was responsible for negative IL-2-induced signaling we observed. Alternatively, a splice isoform of IL-2Rb chain in tumor cells could be responsible, through the generation of shorter signal protein. It was also possible that the absence of functional g chain, which associates with IL2Rb, could contribute to altered signaling in tumor cells. We, therefore, examined these possibilities by performing molecular analysis of the IL-2Rb chain and probing for expression of the associated signaling elements in tumor and control (lymphoid) cells. Starting with total cellular RNA, we performed RT ± PCR of IL-2Rb, using a variety of PCR primer pairs, which cover almost the entire 1.7 kb coding region of IL-2Rb cDNA (Table 3) . Despite initial di®culties with PCR ampli®cation of the intracytoplasmic region downstream from nucleotide 1216, we were able to show that human tumor cells and lymphocytes express the same IL-2Rb chain message. This ®nding was con®rmed by direct sequencing of the PCRampli®ed portion (nucleotides 1216 ± 1815) of genomic DNA from one of the tumor cell lines and YT control cells, as well as by Northern and Western analyses. The results are consistent with various observations in our laboratory, which indicate that the same IL-2/IL-2R pathway present in lymphoid cells is also operative in normal epithelial (e.g., keratinocytes) and carcinoma cells (Lin et al., 1995) .
Negative growth signaling observed with exogenous IL-2 in tumor cells is not related to genetic modi®cations of the b chain. While the presence of a mutation or cryptic splice in the proline-rich intracytoplasmic region IL-2Rb chain, which contains Tyr 392 and Tyr 510 required for activation of STAT 5 transcription factor, could have provided an explanation for inhibitory eects of IL-2 on tumor cells, other possibilities have to be considered. For example, the absence of the g chain, which is involved in IL-2 signaling (Johnston et al., 1996) , and which is associated with the b chain (Takeshita et al., 1992) , could be responsible for altered functions of the IL-2R complex on tumor cells. However, equivalent expression of the g chain protein as well as its transcripts (Lin, et al., 1995) in both control lymphoid and tumor cells rules out this possibility. The family of Janus kinases is an obligatory participant in the signaling of a number of cytokine receptors, with JAK1 and JAK3 known to associate with the b and g chains of IL-2R, respectively (Johnston et al., 1996) . There is evidence in the literature that JAK3B splice variant is expressed in human carcinomas, and that this isoform is de®cient in kinase activity (Lai, et al., 1995) . This may alter intracellular responses to IL-2 signaling. We have, therefore, investigated expression of JAK1 and JAK3 transcripts in our tumor cell lines and found that both JAK1 and JAK3-S form transcripts were present at levels comparable to those in normal lymphocytes. However, the absence or low levels of expression of B or M JAK3 splice variants and very low expression, if any, of common JAK3 in HR which we observed could, contribute to altered downstream signaling mediated via the IL-2R in tumor cells.
We have observed that concentrations of exogenous IL-2 that induce growth inhibition in cultured tumor cells generally exceed 100 nM. At such elevated concentrations, exogenous recombinant IL-2 is likely to eectively compete with endogenously-produced IL- 2 for binding to the IL-2Rb. We have shown previously that endogenously produced IL-2 binds to IL-2Rb on tumor cells, promoting carcinoma growth in vitro, and thus may serve as an autocrine or juxtacrine growth factor for these cells (Lin et al., 1995; Reichert et al., 1997) . Endogenous IL-2 and IL2Rb appear to be necessary for carcinoma growth, as attempts to interfere with expression of either, using speci®c antisense oligonucleotides abolished tumor growth (Lin et al., 1995; Reichert et al., 1997) . Growth-promoting vs. growth inhibitory signals delivered to the IL-2Rb chain by endogenous vs exogenous IL-2, respectively, appear to lead to activation of dierent signaling pathways. The fact that IL-15 binding to the IL-2Rb had no eect on growth, of our tumor cell lines, while IL-2 interacting via the same bg receptor chains inhibited growth of these cells, also points to dierent downstream eects possibly involving distinct receptors (IL-15Rx) and signaling molecules (Bamford et al., 1977) . Alternatively IL-15, which is abundantly expressed in our tumor cell lines (unpublished data) could inhibit eects of recombinant protein. Preliminary evidence indicates that exogenous IL-2 interferes with or disrupts the endogenous IL-2 pathway in carcinoma cells, leading to cell cycle arrest. If con®rmed, this type of mechanism could explain the growth inhibitory eects of high levels of exogenous IL-2 on carcinoma cells. Still another possibility maybe that IL-2 produced by carcinoma cells and involved in tumor cell proliferation diers in some way from exogenous IL-2, and thus distinct signaling occurs when these similar, but not identical, ligands bind to the common receptor.
The mechanism through which the endogenous vs. exogenous IL-2 ligand modulates growth of carcinomas is under investigation in our laboratory. An understanding of this pathway is necessary, because of a possibility that it can be manipulated in the future to control tumor cell proliferation not only in vitro but also in vivo.
Materials and methods
Cell lines
Several human carcinoma cell lines: squamous cell carcinomas of the head and neck, PCI-1 and PCI-13; gastric carcinoma metastic to liver, HR; and renal cell carcinoma, RCC, previously established in our laboratory, were used in the experiments described below. NK cell-like cell line, YT and IL-2-activated human NK (A-NK) cells or a Jurkat T cell line were used as hematopoietic cell controls. In some experiments, normal mitogen-activated human peripheral blood lymphocytes were used as controls. For genomic sequence analysis, only PCI-1 and YT cell lines were used. All cell lines were maintained in culture as previously described (Yasumura et al., 1994; Lin et al., 1995) . To prepare single cell suspensions from monolayers, cultures wee incubated in the presence of a cell dissociation solution (Sigma, St. Louis, MO).
Immunostaining for IL-2Rb or g chains
Tumor cell suspensions were cytofuged onto glass slides, using Shandon centrifuge and ®xed with 2% paraformaldehyde for 5 min. Tumor samples were embedded in OCT and 6 mm sections were cut, air dried and ®xed with acetone. Cytospins or cryostat tumor sections were stained by an indirect immunoperoxidase (IP) method (Chen et al., 1987) , using anti-IL-2R b mAb (TU27) generously provided by Ajinomoto Co., Inc. (Kawasaki, Japan) or anti-common g chain chicken polyclonal Ab purchased from Promega, Madison, WI. The antibody working dilutions (10 mg/ml for TU27 and 50 mg/ml for chicken Ab) were determined in preliminary titration experiments, using YT lymphoid cells. Isotype control Abs purchased from Dako Corporation (Carpinteria, CA) were used in all experiments.
Flow cytometry for expression of IL-2Rg chain
Lymphoid cells used as controls or tumor cell suspensions were stained with polyclonal chicken anti-human gc antibody (Promega), followed by FITC-labeled goat antichicken IgG under conditions described previously (Lin et al., 1995) . For intracytoplasmic staining, cells were pre®xed with 0.5% (w/v) paraformaldehyde for 20 min at 48C and then permeabilized with cold acetone for 3 min, washed and stained with chicken anti-human g-chain Ab (10 mg/200 ml) and subsequently with FITC-labeled goatanti-chicken IgG at 0.25 mg/200 ml (Promega). Isotype controls and PBS alone were used as controls in all experiments. All analyses were formed in a FACScan¯ow cytometer (Becton Dickinson).
Growth inhibition experiments
PCI-1, a SCCHN cell line established in our laboratory and previously described (Weidmann et al., 1992) was cultured in RPMI medium in the presence of 1% (v/v) heat-inactivated fetal calf serum. Tumor cells were plated at the density of 5610 3 cells/well, and 24 h later, various concentrations of recombinant IL-2 (Chiron, Emeryville, CA) or IL-15 (a generous gift from Immunex Corp., Seattle, WA) were added to the monolayers by replacing the medium with 200 ml of cytokine-containing growth medium. The plates were incubated for 3 days and then MTT was added and the colorimetric assay performed as previously described (Heo et al., 1990) . The OD readings obtained from at least three wells per each cytokine concentration were used to calculate the mean % lysis and s.d.
RT ± PCR for IL-2Rb and b-actin in tumor cell lines
Total cellular RNA was prepared from each tumor cell line, using AGPC method (Chomczynski and Sacchi, 1987) followed by DNase I treatment (Promega, Madison, WI). In some cases, mRNA was prepared by a cesium-chloride method. For the IL-2Rb chain RT ± PCR, 150 ng of the total RNA was reverse-transcribed. Forty cycles of PCR were performed (948C, 648C and 728C for 1 min respectively) using several dierent primer pairs listed in Table 3 . Primers 273232, 271844, 262797, 255563, 272438 and 262702 (designated 1516A in Tables 1 and 3) were generously donated by Dr Richard Robb (Dupont, Glenolden, PA) . In case of b-actin, 0.75 ng of total RNA was reverse-transcribed and ampli®ed using 30 PCR cycles and the following primers: 5'-GGGTCAGAAGGATTCC-TATG-3' (sense) and 5'-GGTCTCAAACATGATCTGGG-3' (antisense). The RT ± PCR products were electrophoresed on 1.5% agarose gels, transferred to Hybond N + membranes (Amersham, Arlington Heights, IL) and hybridized with 32 P-labeled cDNA for the IL-2Rb chain (a kind gift from Dr K Sugamura, Tohoku University School of Medicine, Sendai, Japan) or for b-actin. After hybridization at 378C, the membranes were washed at 658C in 0.16SSC/0.1% SDS and exposed to the ®lm (Fugi RX-50) for development of Southern blots.
RT ± PCR analysis for JAK1 and JAK3 expression
Total cellular RNA (200 ng) was prepared as described above from each cell preparation, treated with DNase I and reverse-transcribed, using golden Taq polymerase (Perkin Elmer). For PCR ampli®cation, the following primers were designed, as suggested by Lai and colleagues (1995) , with the exception of primers for JAK1 and JAK3-S form, which were designed by Dr Hassan Farhood at the University of Pittsburgh Cancer Institute:
-GCC ACC AGC CCA TGG AG-3'
PCR was performed for 35 cycles. An annealing temperature of 608C was used for JAK1 and JAK3 common and S-form PCR ampli®cations, but a higher temperature of 688C was used to analyse the expression pattern of JAK3 splice variants B and M. Each PCR reaction contained a reverse transcriptase-negative control and a no-template control. All PCR results were repeated twice. To normalize the RNA levels, b-actin primers were used for 35 cycles at 948C for 1 min, 608C for 1 min and 728C for 1 min. The PCR products were analysed by electrophoresis on 1.5% agarose gels containing ethidium bromide.
Sequence analysis of genomic DNA from tumor cells
Genomic DNA from tumor (PCI-1) or control (YT) cells was extracted and puri®ed, using the Isoquick DNA extraction kit (Microprobe, Garden Grove, CA), according to the manufacturer's directions. One mg of DNA was ampli®ed for 40 cycles (948C, 1 min, 648C and 728C for 2 min respectively) in a volume of 100 ml containing 2 mM MgCl 2 , 0.2 mM dNTP and 5 U of Taq polymerase, using the primer pairs listed in Table 1 . The PCR product was analysed by electrophoresis to check for the presence of a single band. Removal of PCR primers and dNTPs, as well as concentration of the PCR products was performed by the use of Micron 100 concentrators (Amicon, Beverly, MA). Direct sequencing of the double-stranded PCR product was performed by a modi®cation of the standard dideoxynucleotide chain terminating method (Sanger et al., 1977) . PCR products were directly sequenced with uorescent dye-labeled dideoxynucleotides and cycle sequencing methodology (McCombie et al., 1992) , using the Taq DyeDeoxy Terminator Cycle Sequencing Kit (ABI, Foster City, CA). Sequencing products were puri®ed of unincorporated dye-labeled dideoxynucleotides by processing through Centri-Sep spin columns (Princeton Separations, Princeton, NJ) and were electrophoretically fractionated through 6% denaturing polyacrylamide gels (0.4 mm thick). Electrophoresis, band visualization, and sequence analysis were automatically performed on the Applied Biosystems 373A automatic sequencer.
Immunoprecipitation and Western blot analysis
HR and YT cells were incubated in NP-40 lysis buer containing 50 mM HEPES pH 7.2, 150 mM NaCl, 5 mM EDTA, 1 mM orthovandate, 1% NP-40 200 mg/ml trypsin/ chymotrypsin inhibitor (Sigma, St Louis, MO), 200 mg/ml chymostatin (Boehringer-Mannheim, Indianapolis, IN), 2 mM PMSF (Sigma) for 30 min at 48C. Cell lysates were then centrifuged at 14 000 r.p.m. for 10 min and postnuclear supernatants were harvested. The lysates were precleared with 30 ml of a 50% suspension of protein ASepharose beads for 2 h at 48C. Precleared cell lysates were incubated with anti-IL-2Rb mAB (TU27) or normal rabbit IgG (1 mg/100 m1/5610 6 cells) for 16 h at 48C, and immune complexes were bound to protein A-Sepharose beads during additional 2 h of agitation at 48C. The protein Abound immune complexes were preincubated, and washed three times with each of the following buers: PBS/1% NP40, Tris-LiCl and Tris-NaCl-EDTA. The samples were then boiled and electrophoresed in 10% SDS-polyacrylamide gels under reducing conditions. The separated proteins were then electrophoretically transferred to PVDF membrane, Immobilon-P, Millipore (Bedford, MA). Following blocking by 3% solution of nonfat dried milk and 1% BSA for 1 h at room temperature, the membranes were blotted with 2 mg/ml IL-2Rb-speci®c mAb 341 (a gift from Dr P Sondel, University of Wisconsin) at room temperature for 1 h. After washing in Tris-buered saline with 0.05% Tween-20, the membrane was incubated with horseradish peroxidase-conjugated anti-mouse immunoglobulin (1 : 5000 dilution, Amersham) for 1 h. Protein bands were detected by enhanced chemiluminescence.
Northern blot analysis
Total RNA was extracted from cell lines by solubilization in 4M guanidine isothiocyanate followed by ultracentrifugation through a cesium chloride gradient, or using TriReagent (Molecular Research Center), according to the manufacturer's directions. Ten-20 mg of total RNA were size separated on agarose-formaldehyde gel, blotted onto Hybond-N nylon membrane (Amersham), covalently bound by U.V. crosslinking and hybridized to 32 P-labeled IL-2Rb cDNA probe with speci®c activity of 1610 9 c.p.m./ mg. After hybridization for 26 h, the membrane was washed in high salt solution (26SSC/0.1%SDS) twice at 658C, followed by low salt solution (0.16SSC/1%SDS) twice at 658C. Blots were exposed to Kodak Bio-Max ®lm at 7708C with itensifying screen for 7 days.
